Related Experiment Video

Updated: May 8, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Triterpenoids as reversal agents for anticancer drug resistance treatment

Xiao-Jian Yan1, Li-Hua Gong1, Fei-Yun Zheng1

  • 1Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325000, China.

Drug Discovery Today
|August 20, 2013
PubMed

Insights

Triterpenoids show promise in overcoming multidrug resistance (MDR) in cancer by acting as MDR modulators and chemosensitizers, offering potential new strategies for cancer treatment.

Area of Science:

  • Pharmacology
  • Oncology
  • Biochemistry

Background:

  • Multidrug resistance (MDR) in cancer, driven by ATP-binding cassette (ABC) transporters, significantly hinders chemotherapy efficacy.
  • Current strategies to overcome MDR have not translated successfully into clinical practice.
  • Triterpenoids are emerging as potential agents to reverse MDR and enhance anticancer drug sensitivity.

Purpose of the Study:

  • To review recent findings on the role of triterpenoids in reversing cancer multidrug resistance.
  • To evaluate triterpenoids as modulators of MDR and potential chemosensitizers.
  • To discuss future clinical prospects for triterpenoid-based MDR modulation.

Main Methods:

  • Literature review of studies investigating triterpenoids and their effects on MDR.
  • Analysis of evidence demonstrating triterpenoids as MDR reversal agents.
  • Synthesis of current knowledge on triterpenoids' mechanisms in overcoming drug resistance.

Main Results:

  • Triterpenoids exhibit significant potential as modulators of multidrug resistance.
  • These compounds act as chemosensitizers, enhancing the efficacy of anticancer drugs.
  • Evidence supports their role in overcoming resistance mediated by ABC transporters.

Conclusions:

  • Triterpenoids represent a promising class of compounds for reversing cancer multidrug resistance.
  • Their application as chemosensitizers warrants further investigation for clinical translation.
  • Future research should focus on optimizing triterpenoid-based strategies for MDR modulation in cancer therapy.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...